nach oben

Inflammation

Erschienen in:

01.02.2015

The Association Between Systemic Sclerosis, Arginine and Asymmetric Dimethylarginine

verfasst von: Li Zhang, Ya-Nan Wan, Jiu-Hua Zhao, Yu-Jie Wang, Ying-xin Wang, Jun-Wei Yan, Xiao-Lei Huang, Jing Wang

Erschienen in: Inflammation | Ausgabe 1/2015

Einloggen, um Zugang zu erhalten

Abstract

Systemic sclerosis (SSc) is a kind of autoimmune disease characterized by inflammatory and endothelial dysfunction. Asymmetric dimethylarginine (ADMA), as an endogenous nitric oxide synthase inhibitor, can cause or contribute to the inflammatory syndrome and endothelial dysfunction. Recently, increased ADMA levels have been demonstrated in SSc, revealing that ADMA might play an important role for the associated manifestations of SSc. Besides, ADMA may play a significant role in the level of NO, which is produced by arginine. In the review, we discuss the role of arginine and ADMA in patients with SSc.

Sgonc, R., M.S. Gruschwitz, G. Boeck, N. Sepp, J. Gruber, and G. Wick. 2000. Endothelial cell apoptosis in systemic sclerosis is induced by antibody-dependent cell-mediated cytotoxicity via CD95. Arthritis and Rheumatism 43: 2550–2562.CrossRefPubMed

Herrick, A.L. 2005. Pathogenesis of Raynaud’s phenomenon. Rheumatology (Oxford, England) 44: 587–596.CrossRef

Kahaleh, M.B. 1991. Endothelin, an endothelial-dependent vasoconstrictor in scleroderma. Enhanced production and profibrotic action. Arthritis and Rheumatism 34: 978–983.CrossRefPubMed

Denton, C.P., M.C. Bickerstaff, X. Shiwen, M.T. Carulli, D.O. Haskard, R.M. Dubois, and C.M. Black. 1995. Serial circulating adhesion molecule levels reflect disease severity in systemic sclerosis. British Journal of Rheumatology 34: 1048–1054.CrossRefPubMed

Pignone, A., C. Scaletti, M. Matucci-Cerinic, D. Vazquez-Abad, P.L. Meroni, N. Del Papa, F. Falcini, S. Generini, N. Rothfield, and M. Cagnoni. 1998. Anti-endothelial cell antibodies in systemic sclerosis: Significant association with vascular involvement and alveolo-capillary impairment. Clinical and Experimental Rheumatology 16: 527–532.PubMed

Kahaleh, B., P. Fan, M. Matucci-Cerinic, M. Stefanovic-Racic, and L. Ignarro. 1993. Study of endothelial dependent relaxation in scleroderma. Arthritis and Rheumatism 36: S180.

Kahaleh, B., and P. Fan. 1998. Down regulation of nitric oxide synthase gene in microvascular endothelial cells from lesional scleroderma: Assessment by quantitative RT-PCR and possible role for cytotoxic T-cells. Arthritis and Rheumatism 41: S277.

Yamamoto, T., I. Katayama, and K. Nishioka. 1998. Nitric oxide production and inducible nitric oxide synthase expression in systemic sclerosis. The Journal of Rheumatology 25: 314–317.PubMed

Cotton, S.A., A.L. Herrick, M.I. Jayson, and A.J. Freemont. 1999. Endothelial expression of nitric oxide synthases and nitrotyrosine in systemic sclerosis skin. The Journal of Pathology 189: 273–278.CrossRefPubMed

10.

Andersen, G.N., K. Caidahl, E. Kazzam, A.S. Petersson, A. Waldenstrom, L. Mincheva-Nilsson, and S. Rantapaa-Dahlqvist. 2000. Correlation between increased nitric oxide production and markers of endothelial activation in systemic sclerosis: Findings with the soluble adhesion molecules E-selectin, intercellular adhesion molecule 1, and vascular cell adhesion molecule 1. Arthritis and Rheumatism 43: 1085–1093.CrossRefPubMed

11.

Boger, R.H., S.M. Bode-Boger, W. Thiele, W. Junker, K. Alexander, and J.C. Frolich. 1997. Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arterial occlusive disease. Circulation 95: 2068–2074.CrossRefPubMed

12.

Cals-Grierson, M.M., and A.D. Ormerod. 2004. Nitric oxide function in the skin. Nitric Oxide: Biology and Chemistry/Official Journal of the Nitric Oxide Society 10: 179–193.CrossRef

13.

Clancy, R.M., A.R. Amin, and S.B. Abramson. 1998. The role of nitric oxide in inflammation and immunity. Arthritis and Rheumatism 41: 1141–1151.CrossRefPubMed

14.

Matucci Cerinic, M., and M.B. Kahaleh. 2002. Beauty and the beast. The nitric oxide paradox in systemic sclerosis. Rheumatology (Oxford, England) 41: 843–847.CrossRef

15.

Boger, R.H., P. Vallance, and J.P. Cooke. 2003. Asymmetric dimethylarginine (ADMA): A key regulator of nitric oxide synthase. Atherosclerosis Supplements 4: 1–3.CrossRefPubMed

16.

Vallance, P., and J. Leiper. 2004. Cardiovascular biology of the asymmetric dimethylarginine: Dimethylarginine dimethylaminohydrolase pathway. Arteriosclerosis, Thrombosis, and Vascular Biology 24: 1023–1030.CrossRefPubMed

17.

Rajagopalan, S., D. Pfenninger, C. Kehrer, A. Chakrabarti, E. Somers, R. Pavlic, D. Mukherjee, R. Brook, L.G. D’Alecy, and M.J. Kaplan. 2003. Increased asymmetric dimethylarginine and endothelin 1 levels in secondary Raynaud's phenomenon: Implications for vascular dysfunction and progression of disease. Arthritis and Rheumatism 48: 1992–2000.CrossRefPubMed

18.

Landar, A., and V.M. Darley-Usmar. 2003. Nitric oxide and cell signaling: Modulation of redox tone and protein modification. Amino Acids 25: 313–321.CrossRefPubMed

19.

Patel, R.P., A. Levonen, J.H. Crawford, and V.M. Darley-Usmar. 2000. Mechanisms of the pro- and anti-oxidant actions of nitric oxide in atherosclerosis. Cardiovascular Research 47: 465–474.CrossRefPubMed

20.

Dooley, A., B. Gao, N. Bradley, D.J. Abraham, C.M. Black, M. Jacobs, and K.R. Bruckdorfer. 2006. Abnormal nitric oxide metabolism in systemic sclerosis: Increased levels of nitrated proteins and asymmetric dimethylarginine. Rheumatology (Oxford, England) 45: 676–684.CrossRef

21.

Takagi, K., Y. Kawaguchi, M. Hara, T. Sugiura, M. Harigai, and N. Kamatani. 2003. Serum nitric oxide (NO) levels in systemic sclerosis patients: Correlation between NO levels and clinical features. Clinical and Experimental Immunology 134: 538–544.CrossRefPubMedCentralPubMed

22.

Romero, L.I., D.N. Zhang, J.P. Cooke, H.K. Ho, E. Avalos, R. Herrera, and G.S. Herron. 2000. Differential expression of nitric oxide by dermal microvascular endothelial cells from patients with scleroderma. Vascular Medicine (London, England) 5: 147–158.CrossRef

23.

Freedman, R.R., R. Girgis, and M.D. Mayes. 1999. Endothelial and adrenergic dysfunction in Raynaud’s phenomenon and scleroderma. The Journal of Rheumatology 26: 2386–2388.PubMed

24.

Kooy, N.W., J.A. Royall, Y.Z. Ye, D.R. Kelly, and J.S. Beckman. 1995. Evidence for in vivo peroxynitrite production in human acute lung injury. American Journal of Respiratory and Critical Care Medicine 151: 1250–1254.PubMed

25.

Agostoni, A., B. Marasini, M.L. Biondi, C. Bassani, A. Cazzaniga, B. Bottasso, and M. Cugno. 1991. L-arginine therapy in Raynaud’s phenomenon? International Journal of Clinical & Laboratory Research 21: 202–203.CrossRef

26.

Freedman, R.R., R. Girgis, and M.D. Mayes. 1999. Acute effect of nitric oxide on Raynaud’s phenomenon in scleroderma. Lancet 354: 739.CrossRefPubMed

27.

Giuggioli, D., M. Colaci, M. Sebastiani, and C. Ferri. 2010. L-Arginine in pregnant scleroderma patients. Clinical Rheumatology 29: 937–939.CrossRefPubMed

28.

Dimitroulas, T., G. Giannakoulas, K. Papadopoulou, H. Karvounis, H. Dimitroula, G. Koliakos, T. Karamitsos, D. Parcharidou, and L. Settas. 2010. Early detection of cardiac involvement in systemic sclerosis assessed by tissue-Doppler echocardiography: Relationship with neurohormonal activation and endothelial dysfunction. The Journal of Rheumatology 37: 993–999.CrossRefPubMed

29.

Ciurzynski, M., P. Bienias, K. Irzyk, M. Kostrubiec, Z. Bartoszewicz, M. Siwicka, A. Stelmaszczyk-Emmel, E. Gorska, U. Demkow, and P. Pruszczyk. 2014. Serum endothelin-1 and NT-proBNP, but not ADMA, endoglin and TIMP-1 levels, reflect impaired right ventricular function in patients with systemic sclerosis. Clinical Rheumatology 33: 83–89.CrossRefPubMedCentralPubMed

30.

Blaise, S., R. Maas, C. Trocme, G.D. Kom, M. Roustit, P.H. Carpentier, and J.L. Cracowski. 2009. Correlation of biomarkers of endothelium dysfunction and matrix remodeling in patients with systemic sclerosis. The Journal of Rheumatology 36: 984–988.CrossRefPubMed

31.

Turiel, M., L. Gianturco, C. Ricci, P. Sarzi-Puttini, L. Tomasoni, G. Colonna Vde, P. Ferrario, O. Epis, and F. Atzeni. 2013. Silent cardiovascular involvement in patients with diffuse systemic sclerosis: A controlled cross-sectional study. Arthritis Care & Research 65: 274–280.CrossRef

32.

Dimitroulas, T., G. Giannakoulas, K. Papadopoulou, T. Sfetsios, H. Karvounis, H. Dimitroula, D. Parcharidou, G. Koliakos, A. Garyfallos, I. Styliadis, et al. 2010. Left atrial volume and N-terminal pro-B type natriuretic peptide are associated with elevated pulmonary artery pressure in patients with systemic sclerosis. Clinical Rheumatology 29: 957–964.CrossRefPubMed

33.

Dimitroulas, T., G. Giannakoulas, T. Sfetsios, H. Karvounis, H. Dimitroula, G. Koliakos, and L. Settas. 2008. Asymmetrical dimethylarginine in systemic sclerosis-related pulmonary arterial hypertension. Rheumatology (Oxford, England) 47: 1682–1685.CrossRef

34.

Wipff, J., J. Avouac, D. Borderie, D. Zerkak, H. Lemarechal, A. Kahan, C. Boileau, and Y. Allanore. 2008. Disturbed angiogenesis in systemic sclerosis: High levels of soluble endoglin. Rheumatology (Oxford, England) 47: 972–975.CrossRef

35.

Moncada, S., R.M. Palmer, and E.A. Higgs. 1991. Nitric oxide: Physiology, pathophysiology, and pharmacology. Pharmacological Reviews 43: 109–142.PubMed

36.

Giaid, A., and D. Saleh. 1995. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. The New England Journal of Medicine 27: 214–221.CrossRef

37.

Tomita, H., K. Egashira, Y. Ohara, M. Takemoto, M. Koyanagi, M. Katoh, H. Yamamoto, K. Tamaki, H. Shimokawa, and A. Takeshita. 1998. Early induction of transforming growth factor-beta via angiotensin II type 1 receptors contributes to cardiac fibrosis induced by long-term blockade of nitric oxide synthesis in rats. Hypertension 32: 273–279.CrossRefPubMed

38.

Leiper, J., J. Murray-Rust, N. McDonald, and P. Vallance. 2002. S-nitrosylation of dimethylarginine dimethylaminohydrolase regulates enzyme activity: Further interactions between nitric oxide synthase and dimethylarginine dimethylaminohydrolase. Proceedings of the National Academy of Sciences of the United States of America 99: 13527–13532.CrossRefPubMedCentralPubMed

39.

Kahaleh, M.B., and P.S. Fan. 1997. Mechanism of serum-mediated endothelial injury in scleroderma: Identification of a granular enzyme in scleroderma skin and sera. Clinical Immunology and Immunopathology 83: 32–40.CrossRefPubMed

40.

Drenk, F., and H.R. Deicher. 1988. Pathophysiological effects of endothelial cytotoxic activity derived from sera of patients with progressive systemic sclerosis. The Journal of Rheumatology 15: 468–474.PubMed

Titel: The Association Between Systemic Sclerosis, Arginine and Asymmetric Dimethylarginine
verfasst von: Li Zhang
Ya-Nan Wan
Jiu-Hua Zhao
Yu-Jie Wang
Ying-xin Wang
Jun-Wei Yan
Xiao-Lei Huang
Jing Wang
Publikationsdatum: 01.02.2015
Verlag: Springer US
Erschienen in: Inflammation / Ausgabe 1/2015
Print ISSN: 0360-3997
Elektronische ISSN: 1573-2576
DOI: https://doi.org/10.1007/s10753-014-0025-9

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

The Association Between Systemic Sclerosis, Arginine and Asymmetric Dimethylarginine

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Viel Bewegung in der Parkinsonforschung

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2015

Early Administration of Cisatracurium Attenuates Sepsis-Induced Diaphragm Dysfunction in Rats

Protective Effect of Naringenin Against Lipopolysaccharide-Induced Injury in Normal Human Bronchial Epithelium via Suppression of MAPK Signaling

The Development of Early-Onset Ventilator-Associated Pneumonia after Cardiac Surgery with Cardiopulmonary Bypass is Associated with Toll-like Receptor 4 Signal Transduction Pathways

NLRP3 Inflammasome Activation Is Essential for Paraquat-Induced Acute Lung Injury

Systemic and Flap Inflammatory Response Associates with Thrombosis in Flap Venous Crisis

CCR5 Blockade Promotes M2 Macrophage Activation and Improves Locomotor Recovery After Spinal Cord Injury in Mice

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Viel Bewegung in der Parkinsonforschung

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Innere Medizin